247 related articles for article (PubMed ID: 18834937)
1. Intrabody and Parkinson's disease.
Zhou C; Przedborski S
Biochim Biophys Acta; 2009 Jul; 1792(7):634-42. PubMed ID: 18834937
[TBL] [Abstract][Full Text] [Related]
2. Autosomal dominant Parkinson's disease and the route to new therapies.
Morris HR
Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases.
Messer A; McLear J
BioDrugs; 2006; 20(6):327-33. PubMed ID: 17176119
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease: from monogenic forms to genetic susceptibility factors.
Lesage S; Brice A
Hum Mol Genet; 2009 Apr; 18(R1):R48-59. PubMed ID: 19297401
[TBL] [Abstract][Full Text] [Related]
6. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease.
Wang Z; Gao G; Duan C; Yang H
Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236
[TBL] [Abstract][Full Text] [Related]
7. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity.
Lynch SM; Zhou C; Messer A
J Mol Biol; 2008 Mar; 377(1):136-47. PubMed ID: 18237741
[TBL] [Abstract][Full Text] [Related]
8. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.
Joshi SN; Butler DC; Messer A
MAbs; 2012; 4(6):686-93. PubMed ID: 22929188
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against alpha-synuclein: tools and therapies.
Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
[TBL] [Abstract][Full Text] [Related]
10. Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts.
Bhatt MA; Messer A; Kordower JH
J Parkinsons Dis; 2013; 3(4):581-91. PubMed ID: 24270241
[TBL] [Abstract][Full Text] [Related]
11. Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells.
Ortiz-Ortiz MA; Morán JM; Ruiz-Mesa LM; Niso-Santano M; Bravo-SanPedro JM; Gómez-Sánchez R; González-Polo RA; Fuentes JM
Neurosci Lett; 2010 Jan; 468(2):120-4. PubMed ID: 19879924
[TBL] [Abstract][Full Text] [Related]
12. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.
Lastres-Becker I; Ulusoy A; Innamorato NG; Sahin G; Rábano A; Kirik D; Cuadrado A
Hum Mol Genet; 2012 Jul; 21(14):3173-92. PubMed ID: 22513881
[TBL] [Abstract][Full Text] [Related]
13. Impact of recent genetic findings in Parkinson's disease.
Klein C; Lohmann-Hedrich K
Curr Opin Neurol; 2007 Aug; 20(4):453-64. PubMed ID: 17620882
[TBL] [Abstract][Full Text] [Related]
14. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
Konno T; Siuda J; Wszolek ZK
Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
[TBL] [Abstract][Full Text] [Related]
15. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases.
Cardinale A; Biocca S
Trends Mol Med; 2008 Sep; 14(9):373-80. PubMed ID: 18693139
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
17. Computational affinity maturation of camelid single-domain intrabodies against the nonamyloid component of alpha-synuclein.
Mahajan SP; Meksiriporn B; Waraho-Zhmayev D; Weyant KB; Kocer I; Butler DC; Messer A; Escobedo FA; DeLisa MP
Sci Rep; 2018 Dec; 8(1):17611. PubMed ID: 30514850
[TBL] [Abstract][Full Text] [Related]
18. Genetics of Parkinson's disease.
Bonifati V
Minerva Med; 2005 Jun; 96(3):175-86. PubMed ID: 16175160
[TBL] [Abstract][Full Text] [Related]
19. Protein misfolding and aggregation in Parkinson's disease.
Tan JM; Wong ES; Lim KL
Antioxid Redox Signal; 2009 Sep; 11(9):2119-34. PubMed ID: 19243238
[TBL] [Abstract][Full Text] [Related]
20. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
